Drugs / Quinagolide

Trials 4

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 24 trials · 1 met primary · 1 missed
Phase 2 NCT03749109 Aug 2019 → Jun 2021 endometriosis Ferring Pharmaceuticals Completed Missed primary
Phase 2 NCT03692403 Dec 2018 → Feb 2022 endometriosis Ferring Pharmaceuticals Completed No outcome recorded
Phase 2 NCT00665041 May → Aug 2008 ovarian hyperstimulation syndrome Instituto Valenciano de Infertilidad, IVI VALENCIA Completed No outcome recorded
Phase 2 NCT00329693 Jun 2006 → Aug 2007 ovarian hyperstimulation syndrome Ferring Pharmaceuticals Completed Met primary
Comparator or background therapy1 trial
Phase 4 NCT04107480 Comparator Jun 2019 → Mar 2024 prolactin-producing pituitary gland adenoma Leiden University Medical Center Unknown No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Quinagolide “The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.” PMID 20139430 ↗ Feb 2010
4

“Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide.” NCT04107480 ↗

NCT03692403 ↗

NCT03749109 ↗

NCT00665041 ↗

Known as Quinagolida ChEMBL registry synonym — accepted as the source's own label CHEMBL2218861 ↗
Action Activate “Dopamine D2 receptor agonist” CHEMBL2218861 ↗
Action Inhibit “as quinagolide inhibits the VEGF signaling pathway.” PMID 40188683 ↗ Mar 2025
Modality Other / unclassified “non-ergot derived dopamine agonist quinagolide” PMID 20139430 ↗ Feb 2010
Route Oral “three oral doses (50, 100, 200 microg/day)” PMID 20139430 ↗ Feb 2010
Target DRD2 “Dopamine D2 receptor agonist” CHEMBL2218861 ↗